Deutsche Bank upgrades MAP Pharmaceuticals (Nasdaq: MAPP) to Buy. Price target increased from $5 to $12.

Deutsche analyst says, "Despite ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE